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Abstract
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries
(LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This
commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality
evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while
we await results from clinical trials currently conducted in different settings.
Letter to the editor
Neonatal Bacillus Calmette-Guérin (BCG) vaccination is
routine and near-universal in many low- and middle-
income countries (LMIC). By the end of March 2020, dur-
ing the unpreceded global health crisis generated by the
COVID-19 pandemic, a few ecological studies suggested a
protective effect of the BCG vaccine, with less morbidity
and lower mortality from the severe acute respiratory syn-
drome coronavirus-2 (SARS-CoV-2) [1–4]. These studies
have drawn attention to this century-old vaccine and a few
clinical trials are underway to repurpose BCG vaccination.
According to these studies, the incidence of COVID-
19 is four times higher, with a 21-fold increase in death
rates in high- and middle-income countries (HMIC)
without universal BCG vaccination when compared to
those with this policy [1]. The earlier the implementa-
tion of the policy in the country, the lower the number
of COVID-19 related deaths, possibly due to a larger
proportion of vaccinated older adults [1, 2]. However,
those studies included countries that were still in early
phases of the epidemic back then, including Brazil, which
now accounts with the highest number of daily COVID-19
deaths. Also, the observed association was not sustained in
countries with high COVID-19 testing rates [3, 4].
The potential protective effect of neonatal BCG vac-
cination on COVID-19 severity was suggested due to the
lower COVID-19 mortality in some European and Asian
countries (China, South Corea, India, Russia and Japan),
where the vaccination is mandatory [5, 6]. Additionally,
COVID-19 mortality is higher where BCG vaccination
has been discontinued for more than 20 years [7].
France, for instance, registered lower COVID-19 mortal-
ity than Italy, where the vaccination is no longer
mandatory [5–8]. However, there is conflicting data on
the protective effect of BCG vaccination. In Italy, BCG
vaccination was interrupted in 2001 and COVID-19
mortality rates were high among elders [5–8]. In the UK,
where BCG vaccination was recently restarted for TB
high-risk groups such as migrants and individuals living
in social deprived conditions, COVID-19 mortality rates
were higher in these groups than in the overall popula-
tion [5–8]. Finally, countries using the original BCG
strains registered lower COVID-19 case fatality rate if
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compared to European countries that are using modified
BCG strains (Japan - 5.4%; Brazil- 4.7% and Rússia-1.4%
vs France-15.1%, Italy- 14.5% and United Kingdom
14.0%) [5–8], suggesting that different BCG strains can
have different effects on COVID-19 severity and mortal-
ity. Regardless of the controversial findings, ecological
bias and the large numbers of potential confounders,
such as age, socio-economic factors, health system cap-
acity, stage of the epidemic and the proportion of the
population tested, among others, hamper the confiability
of these ecological observations and the inference to the
individual level.
The alleged protective effect could be the result of
trained immunity stimulation from BCG. BCG vaccin-
ation can reduce viremia from other respiratory tract
viral infections [9, 10]. This would be achieved by boost-
ing non-specific Th1 and Th17 responses for at least
one year after vaccination [9], inducing trained immun-
ity, the equivalent of immunological memory for the in-
nate immune response. BCG vaccination followed by a
challenge with attenuated Yellow Fever Virus leads to
macrophage reprogramming, with a central role of inter-
leukin 1 beta (Il-1b), a hallmark of trained immunity [9].
Trained immunity results in a long-lasting functional
programming of innate immune cells that, even in a qui-
escent state, can be recovered by endogenous or exogen-
ous stimuli resulting in a better-regulated response
against a new challenge [11].
In the absence of a specific treatment and vaccine for
COVID-19, even a small protective effect of a cheap and
safe vaccine such as BCG could be a valuable tool for
fighting the disease. If this effect can be confirmed by
higher-quality evidence, BCG vaccine could be used to
improve clinical outcomes of the most vulnerable, redu-
cing the need for hospital beds, ventilators, and the over-
all impact on LMIC countries’ fragile health systems.
Additionally, applied to healthcare professionals, it could
protect the healthcare force, reducing the burden upon
them, and the absenteeism from the disease.
High-income countries without BCG vaccination rec-
ommendations are planning clinical trials to test the
protective effect of BCG on COVID-19 among health-
care workers and older adults [12, 13]. To support the
rationale of these trials, LMIC such as Brazil, where
BCG vaccination has been used since 1929 - with uni-
versal coverage since 1973, are strategic to provide
timely evidence on this potential effect of the BCG vac-
cine, by conducting large case-control studies, which are
usually faster and less expensive than clinical trials. Our
group is currently using Brazilian routine programmatic
data from the existing information systems to analyse
the effect of neonatal BCG immunization on COVID-19
clinical outcomes. In addition, data from a large ran-
domized clinical trial (REVAC-BCG), conducted in over
350 thousand school-aged children in two large Brazilian
cities in 1996–1997 to investigate the effect of BCG vac-
cination and revaccination on tuberculosis is being
linked to the COVID-19 database to provide more in-
sights on this matter [14]. As the BCG revaccination was
ineffective for protection against tuberculosis, the con-
trol arm was not revaccinated; thus, the randomization
carried out in the past is still valid over the years.
Producing high-quality evidence of the effect of BCG
vaccination on COVID-19 outcomes is essential for
decision-makers to eventually recommend the BCG vac-
cination as a possible intervention for COVID-19. We
urge colleagues from LMIC where BCG vaccination pol-
icies are in course to produce fast, trustable, and low-
cost evidence about the effect of the BCG vaccine on the
COVID-19 pandemic, while trials are underway. In case
the results are positive, it would summ up with the re-
sults of the trials in HMIC in course to speed the deci-
sions on the best rationale for using BCG in the current
and future possible waves of the pandemics.
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